Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atorvastatin added to quadruple therapy for Helicobacter pylori eradication
IRCT20201014049020N1Phase 3Completed
- Sponsor
- Hormozgan University of Medical Sciences
- Start
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of atorvastatin in Helicobacter pylori infection (3 arms), sponsored by Hormozgan University of Medical Sciences. Primary endpoints: Effect of atorvastatin on Helicobacter pylori quadruple therapy and Dose effect of atorvastatin on Helicobacter pylori quadruple therapy. Started Nov 2020; status: completed.
02
Drugs
atorvastatin
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on IRCT20201014049020N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20201014049020N1.